Long Noncoding RNA PPP1R14B-AS1 Imitates MicroRNA-134-3p to Facilitate Breast Cancer Progression by Upregulating LIM and SH3 Protein 1

Overview

Journal Oncol Res

Specialty Oncology

Date 2023 Jun 12

PMID 37303940

Authors

Limin Zhou

Lianbo Zhang

Xin Guan

Y I Dong

Tao Liu

Affiliations

Soon will be listed here.

Abstract

Long noncoding RNA PPP1R14B antisense RNA 1 (PPP1R14B-AS1) has emerged as a critical modulator of liver cancer and lung adenocarcinoma progression. However, the functional importance and biological relevance of PPP1R14B-AS1 in breast cancer remain unclear. Therefore, this study was designed to detect PPP1R14B-AS1 levels in breast cancer cells using qRT-PCR and elucidate the influence of PPP1R14B-AS1 on aggressive phenotypes. Furthermore, molecular events mediating the action of PPP1R14B-AS1 were characterized in detail. Functional experiments addressed the impacts of PPP1R14B-AS1 knockdown on breast cancer cells. In this study, PPP1R14B-AS1 was found to be overexpressed in breast cancer, exhibiting a close correlation with poor patient prognosis. Results also showed that breast cancer cell proliferation and motility were suppressed when PPP1R14B-AS1 was silenced. Mechanistically, PPP1R14B-AS1 acted as a competing endogenous RNA for microRNA-134-3p (miR-134-3p) in breast cancer cells. PPP1R14B-AS1 also increased LIM and SH3 protein 1 (LASP1) levels by imitating miR-134-3p in breast cancer cells. Rescue experiments further corroborated that the knockdown of miR-134-3p or an increase in LASP1 restored the aggressive malignant characteristics of breast cancer cells that were weakened by PPP1R14B-AS1 depletion. In summary, PPP1R14B-AS1 facilitated the oncogenicity of breast cancer cells by controlling the miR-134-3p/LASP1 axis. We believe that our findings may contribute to the development of precision therapy techniques in the field of breast cancer treatment.

Citing Articles

PPP1R14B as a potential biomarker for the identification of diagnosis and prognosis affecting tumor immunity, proliferation and migration in prostate cancer.

Bao Y, Ni Y, Zhang A, Chen J J Cancer. 2024; 15(20):6545-6564.

PMID: 39668827 PMC: 11632978. DOI: 10.7150/jca.101100.

lncRNA PAARH impacts liver cancer cell proliferation by engaging miR‑6512‑3p to target LASP1.

Wei Q, Liu G, Huang Z, Nian J, Huang L, Huang Y Oncol Lett. 2024; 28(1):306.

PMID: 38774456 PMC: 11106750. DOI: 10.3892/ol.2024.14439.

References

Chang C, Liu T, Huang Y, Qin W, Yang H, Chen J . MicroRNA-134-3p is a novel potential inhibitor of human ovarian cancer stem cells by targeting RAB27A. Gene. 2017; 605:99-107. DOI: 10.1016/j.gene.2016.12.030. View

Chi F, Qiu F, Jin X, Chen L, He G, Han S . LINC00982 Inhibits the Proliferation, Migration, and Invasion of Breast Cancer Cells Through the miR-765/DPF3 Axis. DNA Cell Biol. 2022; 41(4):424-436. DOI: 10.1089/dna.2021.0866. View

Filippova E, Fridman M, Burdennyy A, Loginov V, Pronina I, Lukina S . Long Noncoding RNA GAS5 in Breast Cancer: Epigenetic Mechanisms and Biological Functions. Int J Mol Sci. 2021; 22(13). PMC: 8267719. DOI: 10.3390/ijms22136810. View

Sui X, Sui Z . MiR-4269 suppresses the tumorigenesis and development of pancreatic cancer by targeting ZEB1/OTX1 pathway. Biosci Rep. 2020; 40(6). PMC: 7286876. DOI: 10.1042/BSR20200010. View

Chen Y, Wang X . miRDB: an online database for prediction of functional microRNA targets. Nucleic Acids Res. 2019; 48(D1):D127-D131. PMC: 6943051. DOI: 10.1093/nar/gkz757. View

Jin H, Du W, Huang W, Yan J, Tang Q, Chen Y . lncRNA and breast cancer: Progress from identifying mechanisms to challenges and opportunities of clinical treatment. Mol Ther Nucleic Acids. 2021; 25:613-637. PMC: 8463317. DOI: 10.1016/j.omtn.2021.08.005. View

Wang C, Zheng X, Shen C, Shi Y . MicroRNA-203 suppresses cell proliferation and migration by targeting BIRC5 and LASP1 in human triple-negative breast cancer cells. J Exp Clin Cancer Res. 2012; 31:58. PMC: 3585778. DOI: 10.1186/1756-9966-31-58. View

Yang G, Lu X, Yuan L . LncRNA: a link between RNA and cancer. Biochim Biophys Acta. 2014; 1839(11):1097-109. DOI: 10.1016/j.bbagrm.2014.08.012. View

Sui Y, Zhang X, Yang H, Wei W, Wang M . MicroRNA-133a acts as a tumour suppressor in breast cancer through targeting LASP1. Oncol Rep. 2017; 39(2):473-482. PMC: 5783615. DOI: 10.3892/or.2017.6114. View

10.

Fang J, Jiang G, Mao W, Huang L, Huang C, Wang S . Up-regulation of long noncoding RNA MBNL1-AS1 suppresses breast cancer progression by modulating miR-423-5p/CREBZF axis. Bioengineered. 2022; 13(2):3707-3723. PMC: 8973591. DOI: 10.1080/21655979.2022.2026728. View

11.

Qi P, Du X . The long non-coding RNAs, a new cancer diagnostic and therapeutic gold mine. Mod Pathol. 2012; 26(2):155-65. DOI: 10.1038/modpathol.2012.160. View

12.

Denkert C, Liedtke C, Tutt A, von Minckwitz G . Molecular alterations in triple-negative breast cancer-the road to new treatment strategies. Lancet. 2016; 389(10087):2430-2442. DOI: 10.1016/S0140-6736(16)32454-0. View

13.

Stojic L, Lun A, Mangei J, Mascalchi P, Quarantotti V, Barr A . Specificity of RNAi, LNA and CRISPRi as loss-of-function methods in transcriptional analysis. Nucleic Acids Res. 2018; 46(12):5950-5966. PMC: 6093183. DOI: 10.1093/nar/gky437. View

14.

Wang J, Wang L, Zhang C . miR-765 Acts as a Tumor Promoter and Indicates Poor Prognosis in Non-Small Cell Lung Cancer. Onco Targets Ther. 2021; 14:4335-4343. PMC: 8349552. DOI: 10.2147/OTT.S284212. View

15.

Yang Y, Zhang Y, Miao L, Liao W, Liao W . LncRNA PPP1R14B-AS1 Promotes Tumor Cell Proliferation and Migration via the Enhancement of Mitochondrial Respiration. Front Genet. 2020; 11:557614. PMC: 7686783. DOI: 10.3389/fgene.2020.557614. View

16.

Grimson A, Farh K, Johnston W, Garrett-Engele P, Lim L, Bartel D . MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol Cell. 2007; 27(1):91-105. PMC: 3800283. DOI: 10.1016/j.molcel.2007.06.017. View

17.

Wang Y, Cui X, Ma S, Zhang H . Decreased expression of miR-3135b reduces sensitivity to 5-fluorouracil in colorectal cancer by direct repression of PIM1. Exp Ther Med. 2021; 22(4):1151. PMC: 8392875. DOI: 10.3892/etm.2021.10585. View

18.

Jiang B, Liu Q, Gai J, Guan J, Li Q . LncRNA SLC16A1-AS1 regulates the miR-182/PDCD4 axis and inhibits the triple-negative breast cancer cell cycle. Immunopharmacol Immunotoxicol. 2022; 44(4):534-540. DOI: 10.1080/08923973.2022.2056482. View

19.

Tang W, Lu G, Ji Y, Xu Y . Long non‑coding RNA PCAT1 sponges miR‑134‑3p to regulate PITX2 expression in breast cancer. Mol Med Rep. 2022; 25(3). DOI: 10.3892/mmr.2022.12591. View

20.

Quintanilha J, Cursino M, Borges J, Torso N, Bastos L, Oliveira J . MiR-3168, miR-6125, and miR-4718 as potential predictors of cisplatin-induced nephrotoxicity in patients with head and neck cancer. BMC Cancer. 2021; 21(1):575. PMC: 8136168. DOI: 10.1186/s12885-021-08317-2. View